Literature DB >> 11906767

Evaluation of vaccines for atrophic rhinitis--a comparison of three challenge models.

T Magyar1, V L King, F Kovács.   

Abstract

We compared three challenge models for the assessment of atrophic rhinitis (AR) vaccines: combined infection with Bordetella bronchiseptica (Bb) and Pasteurella multocida (Pm); application of acetic acid (AA) to the nasal mucosa followed by Pm infection; and Bb infection alone. Two vaccines were tested using standardized criteria, notably nasal lesion scores. The vaccines provided different levels of protection in the Bb and the AA/Pm challenges, but were similar in the combined (Bb/Pm) challenge. It is clear that the AA/Pm model shows the protective value of only the Pm component, whereas the single Bb challenge reflects the protective value merely of the Bb component of a combined vaccine. These results suggest that the best assessment of protection is provided if the two specific challenges are performed separately.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11906767     DOI: 10.1016/s0264-410x(02)00023-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Interaction of Bordetella bronchiseptica, Pasteurella multocida, and fumonisin B1 in the porcine respiratory tract as studied by computed tomography.

Authors:  Roland Pósa; Tamás Donkó; Péter Bogner; Melinda Kovács; Imre Repa; Tibor Magyar
Journal:  Can J Vet Res       Date:  2011-07       Impact factor: 1.310

Review 2.  Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies.

Authors:  Seema Mattoo; James D Cherry
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

Review 3.  Pasteurella multocida: from zoonosis to cellular microbiology.

Authors:  Brenda A Wilson; Mengfei Ho
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

4.  Protective immunity conferred by the C-terminal fragment of recombinant Pasteurella multocida toxin.

Authors:  Jeongmin Lee; Hae-Eun Kang; Hee-Jong Woo
Journal:  Clin Vaccine Immunol       Date:  2012-07-25

5.  Regeneration of toxigenic Pasteurella multocida induced severe turbinate atrophy in pigs detected by computed tomography.

Authors:  Tibor Magyar; Tamás Donkó; Imre Repa; Melinda Kovács
Journal:  BMC Vet Res       Date:  2013-10-30       Impact factor: 2.741

6.  Integrated pharmacokinetic-Pharmacodynamic (PK/PD) model to evaluate the in vivo antimicrobial activity of Marbofloxacin against Pasteurella multocida in piglets.

Authors:  Qing Lin Zeng; Xian Mei; Jia Su; Xiao Hong Li; Wen Guang Xiong; Yan Lu; Zhen Ling Zeng
Journal:  BMC Vet Res       Date:  2017-06-15       Impact factor: 2.741

7.  Screening of 71 P. multocida proteins for protective efficacy in a fowl cholera infection model and characterization of the protective antigen PlpE.

Authors:  Tamás Hatfaludi; Keith Al-Hasani; Lan Gong; John D Boyce; Mark Ford; Ian W Wilkie; Noelene Quinsey; Michelle A Dunstone; David E Hoke; Ben Adler
Journal:  PLoS One       Date:  2012-07-05       Impact factor: 3.240

Review 8.  Developing animal models for polymicrobial diseases.

Authors:  Lauren O Bakaletz
Journal:  Nat Rev Microbiol       Date:  2004-07       Impact factor: 60.633

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.